SinoFresh Reports Patient Case Study: Allergic Fungal Rhinosinusitis in Adult Male With History of Sinus Conditions
Posted on: Thursday, 27 April 2006, 09:00 CDT
SinoFresh HealthCare, Inc. (OTC BB: SFSH), maker of the only over-the-counter nasal spray that eliminates the causes of many chronic sinus conditions, today reported a patient case study involving successful treatment of an extreme case of allergic fungal rhinosinusitis.
Patient History
58-year-old male with over 40 years of chronic sinus problems. He had undergone multiple sinus operations over his lifetime. He presented with persistent frontal sinus pressure, itchiness over the forehead, and thick nasal discharge.
Diagnosis
Laboratory studies of his mucus were extremely positive for major basic protein, confirming a diagnosis of fungal origin of his chronic rhinosinusitis.
Treatment
The patient was placed on SinoFresh(TM) Nasal Mist in an attempt to reduce the fungal load in his nasal cavity. Within a week, his facial itchiness and pressure greatly improved. He also had a remarkable reduction in nasal discharge. After further follow-up, the amount of thickened mucus in his nasal cavity was minimal.
The patient was treated at the renowned Silverstein Institute in Sarasota, FL. As a further complicating factor in this case, the patient is employed as a merchant marine and is onboard sea-going vessels for periods of up to 6 months. It is imperative that the patient has access to a treatment alternative that is portable, easy-to-use, and does not require refrigeration or other special handling procedures.
Seth I. Rosenberg, M.D. of the Silverstein Institute oversaw the case and commented, "This case is a great example of a patient who may have benefited from a prescription antifungal treatment; however due to logistical reasons SinoFresh(TM) was the best first-line alternative." He continued, "I feel that SinoFresh(TM) would also be good for casual use for chronic rhinosinusitis, which could open use for this product to literally millions of people."
William Wilferth, SinoFresh's Vice President of Research & Development, stated, "SinoFresh(TM) has always shown great efficacy against a variety of fungal organisms in laboratory experiments. This case study is another great building block toward establishing SinoFresh(TM) as the physician's first choice for certain chronic sinus conditions."
About SinoFresh HealthCare, Inc.
SinoFresh HealthCare, Inc. is a developer and marketer of innovative upper respiratory system therapies. The Company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial, and fungal organisms that are suspected to cause pathogenesis of the upper respiratory tract. The Company's lead product, SinoFresh(TM) Nasal Mist, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The Company is also researching how antiseptic cleansing may alleviate chronic sinus distress, a condition that may affect 37 million Americans annually. SinoFresh(TM) products are available in Wal-Mart, Walgreens, Rite Aid, CVS, Duane Reade, and other drug, grocery, and mass merchandise retailers. More information is available at www.sinofresh.com.
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including risks summarized in the Company's Annual Report on Form 10-KSB for its fiscal year ended December 31, 2005 (file No. 0-49764). The Company's actual results could differ materially from such forward-looking statements. The Company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments. Adjusted EBITDA is not a measure of performance calculated in accordance with accounting principles generally accepted in the United States, or "GAAP."
SinoFresh(TM) is a trademark of SinoFresh HealthCare, Inc.
Media Contact: Michael Gillette: 941-681-3121 mgillette@sinofresh.com Investor Relations: 941-232-9442 investorrelations@sinofresh.com
SOURCE: SinoFresh Healthcare, Inc.
Source: MARKET WIRE
Related Articles
- NaviMedix Acquires TopLine Solutions Inc., Partners With Financial Information and Services Companies to Deliver "All Payer-All Patient" Payment Solutions for Healthcare Providers
- SinoFresh(R) Nasal Spray Kills MRSA "Super-Bug" in Live Noses
- Enfora to Demonstrate Wireless Patient Monitoring Solutions at Healthcare Unbound
- Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
- Studies Confirm Balloon Sinuplasty(TM) Helps Chronic Sinusitis Patients
- Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- Study Confirms Balloon Sinuplasty(TM) Technology is Safe and Effective for Chronic Sinusitis Patients
- Seventy-Eight Percent of Newly Diagnosed Dyslipidemia Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- A Nested Case-Control Study on Treatment-Related Risk Factors for Early Relapse of Tuberculosis
 |
 |
User Comments (0)
RSS Feeds